三张牌黑暗塔
電話:0532-80822188
青島普愛曜陽中西醫結合醫院
青島海蘭深生物科技 
QingDao HaiLanShen Bio-Technology Co.Ltd
青島海蘭深生物科技有限公司長期致力于人體免疫系統、精準治療等醫藥和醫療技術、產品的研發和核心技術能力的構建,與英國高地與群島大學(The University of the Highlands and Islands)緊密合作,共同開展生物醫藥技術/產品研發. 同時,在國內與首都醫科大學醫院,吉林大學第二附屬醫院,廣東醫學院等共同建立科研臨床驗證基地,將生物醫藥研發成果,在獲得醫學倫理委員會批準后, 開展科研臨床驗證.共同構成本公司自主創新支撐體系。
Qingdao Hailanshen Biotechnology Co., Ltd (QHB) has long been dedicated to the development of medical technologies and products for diagnosis and immunotherapies such as precision treatments of highly fatal malignant diseases and the enzyme-linked immunosorbent assay (ELISA) for detection of plasma antibodies; QHB has established the core technological capabilities and works closely with the University of the Highlands and Islands (UHI) to develop biomedical technology/products. At the same time, QHB has developed several clinical research projects in collaboration with the hospitals for clinical trials and conducted clinical validation of new products, as approved by a Research Ethics Committee. These projects together constitute the company's innovation system
青島海蘭深生物科技,基于多年對抗原抗體研究,與英國高地與群島大學合作,創新開發組合抗原制備酶聯免疫吸附法(ELISA)抗體檢測試劑盒,以篩查富含天然抗癌抗體的健康人血漿。 并利用該部分健康人血漿治療肝癌患者,預防肝癌復發和轉移。取得了B期肝癌病人中位數生存期32個月的顯著療效.該成果論文發表在國際權威癌癥研究雜志 >.該項技術填補了國內外腫瘤治療領域的空白, 具有重大的臨床應用價值。
QHB has been working together with UHI to develop ELISA for detection of anticancer antibodies in human plasma. Initial study suggests that plasma rich in anticancer antibodies could strongly inhibit the proliferation of hepatocellular carcinoma (HCC) cells and raised the possibility for clinical treatment of HCC patients. Such research work has been published in American Journal of Cancer Research (7: 609-609, 2017). Clinical trial of HCC immunotherapy with transfusion of plasma rich in anticancer antibodies has been carried out since 2015, and preliminary outcome demonstrated that patients with stage B HCC had a median survival of 30 months after plasma transfusion was given, as compared with 18 months in those who did not receive plasma transfusion. This therapy is likely a powerful approach for the treatment of patients with stage B HCC and has a significant potential for clinical application.
同時,海蘭深生物科技還在白血病,心血管疾病,糖尿病,延緩衰老等領域開展研究,并有多項技術儲備.
At the same time, Hailan Shen Biotechnology also conducts research in the fields of leukemia, cardiovascular disease, diabetes, anti-aging, and has a number of technical reserves.
公司以創建國內一流的生物醫藥企業為總目標,制定了以生物醫藥為主軸,以中西藥物和精準治療為兩翼“一主兩翼”協同發展的橫向一體化戰略,目前正在逐步落實精準治療的發展戰略,形成從抗原抗體檢測、抗體免疫治療技術/產品、靶向抗腫瘤藥物開發、等一系列精準治療全產業鏈布局,朝著“免疫之王”的宏偉目標不斷進取。
Creation of a domestic first-class biopharmaceutical company is our mission. QHB has formulated an integrative strategy, namely “One main and Two wings”. The development of powerful biomedical technologies is the main axis, and early diagnosis of cancer and precision medication are the two wings, achieving a key competitive edge in natural antibody testing, antibody-based immunotherapy and biopharmaceutically targeted agents. We will rapidly move towards the "immune king" of the ambitious goal of continuous improvement, and continue to make progress towards our vision of “To be immunity research pioneer”.
三张牌黑暗塔 云南11选5开奖公 90足球比分网 幸运飞艇微信计划群 大众麻将怎么玩没有风 31选7 长沙麻将技巧大全图解 比利时对战突尼斯比分预测 山东体彩十一选五开 即时指数即时比分 北京体彩快中彩开奖 牛彩网3d图谜总汇 山东德州麻将卡五魁钓金龟边三饼 宁夏十一选五 新疆十一选五开奖 德州麻将是怎么玩的 河北十一选五*结果